MedTrace Logo

Paracetamol Oral Paediatric Suspension at 4.8% : Study of Acceptability and Safety.

NCT00434681 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2008-07-21

No results posted yet for this study

Summary

Evaluate the acceptability over 24 hours of a new paracetamol formulation 4.8% paediatric oral suspension in children weighing between 3 and 26 kg including limits

Conditions

Interventions

DRUG

paracetamol 4.8% paediatric oral suspension

Sponsors & Collaborators

Principal Investigators

  • Monique COUDERC, Dr · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Day
Max Age
8 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Completion
2007-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00434681 on ClinicalTrials.gov